左乙拉西坦作为新生儿癫痫一线治疗药物的前瞻性研究。
Levetiracetam in Neonatal Seizures as First-line Treatment: A Prospective Study.
作者信息
Falsaperla Raffaele, Vitaliti Giovanna, Mauceri Laura, Romano Catia, Pavone Piero, Motamed-Gorji Nazgol, Matin Nassim, Lubrano Riccardo, Corsello Giovanni
机构信息
Department of Pediatrics, General Paediatrics Operative Unit, Policlinico-Vittorio Emanuele University Hospital, University of Catania, Catania, Italy.
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
出版信息
J Pediatr Neurosci. 2017 Jan-Mar;12(1):24-28. doi: 10.4103/jpn.JPN_172_16.
AIM OF THE STUDY
The aim of this study is to evaluate the efficacy and safety of levetiracetam (LEV) as first-line treatment of neonatal seizures.
MATERIALS AND METHODS
This study was conducted in patients of Neonatal Intensive Care Unit of Santo Bambino Hospital, University of Catania, Italy, from January to August 2016. A total of 16 neonates with convulsions not associated with major syndromes, which required anticonvulsant therapy, were included and underwent IV LEV at standard doses.
RESULTS
All patients responded to treatment, with a variety range of seizure resolution period (from 24 h to 15 days; mean hours: 96 ± 110.95). No patient required a second anticonvulsant therapy. Regarding safety of LEV, no major side-effects were observed.
CONCLUSIONS
To our knowledge, it is one of the few studies confirming the efficiency of LEV as first-line treatment in seizures of this age group. LEV was effective in resolving seizures and was safely administered in the current study.
研究目的
本研究旨在评估左乙拉西坦（LEV）作为新生儿癫痫一线治疗药物的疗效和安全性。
材料与方法
本研究于2016年1月至8月在意大利卡塔尼亚大学圣婴医院新生儿重症监护病房的患者中进行。共有16例与主要综合征无关的惊厥新生儿纳入研究，这些新生儿需要抗惊厥治疗，并接受了标准剂量的静脉注射LEV。
结果
所有患者对治疗均有反应，惊厥缓解期各不相同（从24小时至15天；平均小时数：96±110.95）。没有患者需要第二种抗惊厥治疗。关于LEV的安全性，未观察到重大副作用。
结论
据我们所知，这是少数几项证实LEV作为该年龄组癫痫一线治疗药物有效性的研究之一。在本研究中，LEV在解决惊厥方面有效且给药安全。
Zotero 插件